Becton, Dickinson-BD Boosts U.S. Manufacturing of Critical Medical Devices

Core Viewpoint - BD (Becton, Dickinson and Company) is making significant investments in its U.S. manufacturing network to enhance the production capacity of critical medical devices, including syringes, needles, and IV catheters, in response to the ongoing needs of the healthcare system [1][2]. Investment and Capacity Expansion - In 2024, the company plans to invest over $10 million to expand manufacturing capacity, with new production lines for needles and syringes installed in Connecticut and Nebraska, one of which is already operational [3]. - The new production lines will increase BD's capacity for domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by over 50%, adding hundreds of millions of units annually [4]. Employment and Local Impact - BD has hired more than 215 full-time employees at its facilities in Nebraska and Connecticut to support the increased production [4]. - The company operates over 30 manufacturing and distribution facilities across the U.S., employing more than 10,000 people [7]. Future Plans - BD has plans for more than$ 30 million in investments in 2025 to expand manufacturing capacity for IV lines at its Utah plant, following a previous investment of over $2 million in 2024 that increased IV catheter output by more than 40 million units annually [5]. Commitment to U.S. Healthcare - The investments reflect BD's commitment to ensuring a resilient supply of essential healthcare devices and supporting the U.S. healthcare infrastructure [6]. - BD has a long history of manufacturing excellence in the U.S., with facilities in Nebraska, Connecticut, and Utah collectively having over 200 years of experience in producing critical medical devices [6].